Sysmex Corporation (FRA:0YX)

Market Cap	4.90B -46.6%
Revenue (ttm)	2.73B -1.7%
Net Income	193.40M -33.9%
EPS	0.31 -33.9%
Shares Out	n/a
PE Ratio	25.31
Forward PE	n/a
Dividend	0.21 (2.91%)
Ex-Dividend Date	Mar 30, 2026

Volume	n/a
Open	7.41
Previous Close	7.28
Day's Range	7.41 - 7.41
52-Week Range	6.51 - 15.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co...

• Industry: Laboratory Analytical Instruments
• Founded: 1968
• Employees: 10,533
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0YX

Financial Performance

In fiscal year 2026, Sysmex's revenue was 500.01 billion, a decrease of -1.70% compared to the previous year's 508.64 billion. Earnings were 35.46 billion, a decrease of -33.93%.

Financial numbers in JPY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error